biostudies-literatureUnknown15Li JHeilongjiang University of Chinese Medicine<h4>Background</h4>T cell receptor (TCR)-T cell therapy is an innovative form of cancer immunotherapy that genetically modifies patients' T cells to target and destroy cancer cells. However, the current status of clinical trials of TCR-T cell therapy for the treatment of cancer remains unclear. This study aimed to comprehensively analyze the registration trials related to TCR-T cell therapy for the treatment of cancer.<h4>Methods</h4>A comprehensive search was conducted in the Trialtrove database for all clinical trials related to TCR-T cell therapy registered by August 1, 2024. Inclusion criteria focused on trials targeting TCR-T cell therapy for oncology, and excluded observational studies and incomplete data. Statistical analysis was performed on key trial characteristics, with between-Frontiers in immunology1487782https://www.ebi.ac.uk/biostudies/studies/S-EPMC11493697biostudies-literatureClinical advances and challenges associated with TCR-T cell therapy for cancer treatment.PMC11493697Fu TLi JXing GZhang YTong YLi KCai HXu YfalseClinical advances and challenges associated with TCR-T cell therapy for cancer treatment.<h4>Background</h4>T cell receptor (TCR)-T cell therapy is an innovative form of cancer immunotherapy that genetically modifies patients' T cells to target and destroy cancer cells. However, the current status of clinical trials of TCR-T cell therapy for the treatment of cancer remains unclear. This study aimed to comprehensively analyze the registration trials related to TCR-T cell therapy for the treatment of cancer.<h4>Methods</h4>A comprehensive search was conducted in the Trialtrove database for all clinical trials related to TCR-T cell therapy registered by August 1, 2024. Inclusion criteria focused on trials targeting TCR-T cell therapy for oncology, and excluded observational studies and incomplete data. Statistical analysis was performed on key trial characteristics, with between-2024-01-01T00:00:00Z20242026-07-05T03:08:59.072Z2025-04-06T14:22:58.938ZS-EPMC114936973943980310.3389/fimmu.2024.1487782